{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:02:04Z","timestamp":1791234124586,"version":"4.1.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,1,15]]},"DOI":"10.1093\/infdis\/jis671","type":"journal-article","created":{"date-parts":[[2012,11,3]],"date-time":"2012-11-03T01:35:04Z","timestamp":1351906504000},"page":"248-256","source":"Crossref","is-referenced-by-count":108,"title":["Characterization of Humoral and Cellular Immune Responses Elicited by a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine in Healthy Adults (IPCAVD 001)"],"prefix":"10.1093","volume":"207","author":[{"given":"Dan H.","family":"Barouch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Peter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Abbink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Justin","family":"Iampietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galit","family":"Alter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Dugast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Frahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Juliana","family":"McElrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Wenschuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Reimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Seaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria G.","family":"Pau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mo","family":"Weijtens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap","family":"Goudsmit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen R.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Dolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey R.","family":"Baden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,11,2]]},"reference":[{"key":"key\n\t\t\t\t20170511121854_JIS671C1","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1086\/428404","article-title":"Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection","volume":"191","author":"Flynn","year":"2005","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170511121854_JIS671C2","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1086\/508748","article-title":"Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand","volume":"194","author":"Pitisuttithum","year":"2006","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170511121854_JIS671C3","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"Buchbinder","year":"2008","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170511121854_JIS671C4","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Rerks-Ngarm","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170511121854_JIS671C5","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nature07352","article-title":"Challenges in the development of an HIV-1 vaccine","volume":"455","author":"Barouch","year":"2008","journal-title":"Nature"},{"key":"key\n\t\t\t\t20170511121854_JIS671C6","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1146\/annurev-med-042010-085643","article-title":"New paradigms for HIV\/AIDS vaccine development","volume":"63","author":"Picker","year":"2012","journal-title":"Annu Rev Med"},{"key":"key\n\t\t\t\t20170511121854_JIS671C7","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1126\/science.1161000","article-title":"HIV vaccine research: the way forward","volume":"321","author":"Fauci","year":"2008","journal-title":"Science"},{"key":"key\n\t\t\t\t20170511121854_JIS671C8","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(08)61592-5","article-title":"HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis","volume":"372","author":"McElrath","year":"2008","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170511121854_JIS671C9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1146\/annurev.med.042508.093728","article-title":"HIV-1 vaccine development after STEP","volume":"61","author":"Barouch","year":"2010","journal-title":"Annu Rev Med"},{"key":"key\n\t\t\t\t20170511121854_JIS671C10","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/COH.0b013e32833cfe4c","article-title":"Novel adenovirus vector-based vaccines for HIV-1","volume":"5","author":"Barouch","year":"2010","journal-title":"Curr Opin HIV AIDS"},{"key":"key\n\t\t\t\t20170511121854_JIS671C11","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1128\/JVI.02696-06","article-title":"Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D","volume":"81","author":"Abbink","year":"2007","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20170511121854_JIS671C12","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1016\/j.vaccine.2011.05.025","article-title":"International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations","volume":"29","author":"Barouch","year":"2011","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170511121854_JIS671C13","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nature07469","article-title":"Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys","volume":"457","author":"Liu","year":"2009","journal-title":"Nature"},{"key":"key\n\t\t\t\t20170511121854_JIS671C14","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2008.01.016","article-title":"Adenovirus serotype 5 hexon mediates liver gene transfer","volume":"132","author":"Waddington","year":"2008","journal-title":"Cell"},{"key":"key\n\t\t\t\t20170511121854_JIS671C15","doi-asserted-by":"crossref","first-page":"8263","DOI":"10.1128\/JVI.77.15.8263-8271.2003","article-title":"Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity","volume":"77","author":"Vogels","year":"2003","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20170511121854_JIS671C16","doi-asserted-by":"crossref","first-page":"4844","DOI":"10.1128\/JVI.02616-07","article-title":"Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys","volume":"82","author":"Liu","year":"2008","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20170511121854_JIS671C17","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.4049\/jimmunol.179.3.1721","article-title":"Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responses","volume":"179","author":"Lore","year":"2007","journal-title":"J Immunol"},{"key":"key\n\t\t\t\t20170511121854_JIS671C18","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.vaccine.2009.10.145","article-title":"International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials","volume":"28","author":"Mast","year":"2010","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170511121854_JIS671C19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nature10766","article-title":"Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys","volume":"482","author":"Barouch","year":"2012","journal-title":"Nature"},{"key":"key\n\t\t\t\t20170511121854_JIS671C20","article-title":"First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001)","author":"Baden","year":"2012","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170511121854_JIS671C21","doi-asserted-by":"crossref","first-page":"11502","DOI":"10.1128\/JVI.05363-11","article-title":"Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals","volume":"85","author":"Tomaras","year":"2011","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20170511121854_JIS671C22","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/978-1-60761-845-4_13","article-title":"Antibody signatures defined by high-content peptide microarray analysis","volume":"669","author":"Masch","year":"2010","journal-title":"Methods Mol Biol"},{"key":"key\n\t\t\t\t20170511121854_JIS671C23","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jim.2010.12.016","article-title":"A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples","volume":"366","author":"Ackerman","year":"2011","journal-title":"J Immunol Methods"},{"key":"key\n\t\t\t\t20170511121854_JIS671C24","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jim.2005.09.018","article-title":"A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity","volume":"308","author":"Gomez-Roman","year":"2006","journal-title":"J Immunol Methods"},{"key":"key\n\t\t\t\t20170511121854_JIS671C25","doi-asserted-by":"crossref","first-page":"12449","DOI":"10.1128\/JVI.01708-08","article-title":"Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia","volume":"82","author":"Tomaras","year":"2008","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20170511121854_JIS671C26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jim.2007.03.002","article-title":"Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination","volume":"323","author":"Horton","year":"2007","journal-title":"J Immunol Methods"},{"key":"key\n\t\t\t\t20170511121854_JIS671C27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v012.i05","article-title":"Bioassay analysis using R","volume":"12","author":"Ritz","year":"2005","journal-title":"J Stat Software"},{"key":"key\n\t\t\t\t20170511121854_JIS671C28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2307\/1403201","article-title":"Bioassay and the practice of statistical inference","volume":"47","author":"Finney","year":"1979","journal-title":"Int Stat Rev"},{"key":"key\n\t\t\t\t20170511121854_JIS671C29","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nm.1991","article-title":"Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans","volume":"15","author":"O'Brien","year":"2009","journal-title":"Nat Med"},{"key":"key\n\t\t\t\t20170511121854_JIS671C30","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","article-title":"Immune-correlates analysis of an HIV-1 vaccine efficacy trial","volume":"366","author":"Haynes","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170511121854_JIS671C31","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1172\/JCI60202","article-title":"Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine","volume":"122","author":"Frahm","year":"2012","journal-title":"J Clin Invest"},{"key":"key\n\t\t\t\t20170511121854_JIS671C32","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/j.vaccine.2009.10.091","article-title":"Adenovirus-specific human T cells are pervasive, polyfunctional, and cross-reactive","volume":"28","author":"Hutnick","year":"2010","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20170511121854_JIS671C33","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/nm.1989","article-title":"Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+ T cells","volume":"15","author":"Hutnick","year":"2009","journal-title":"Nat Med"},{"key":"key\n\t\t\t\t20170511121854_JIS671C34","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002925","article-title":"Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species","volume":"4","author":"Colloca","year":"2012","journal-title":"Sci Transl Med"},{"key":"key\n\t\t\t\t20170511121854_JIS671C35","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003155","article-title":"Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man","volume":"4","author":"Barnes","year":"2012","journal-title":"Sci Transl Med"},{"key":"key\n\t\t\t\t20170511121854_JIS671C36","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/infdis\/jir850","article-title":"Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector","volume":"205","author":"O'Hara","year":"2012","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170511121854_JIS671C37","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nm1461","article-title":"Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants","volume":"13","author":"Fischer","year":"2007","journal-title":"Nat Med"},{"key":"key\n\t\t\t\t20170511121854_JIS671C38","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nm.2089","article-title":"Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys","volume":"16","author":"Barouch","year":"2010","journal-title":"Nat Med"},{"key":"key\n\t\t\t\t20170511121854_JIS671C39","doi-asserted-by":"crossref","first-page":"11007","DOI":"10.1128\/JVI.05346-11","article-title":"Durable mucosal simian immunodeficiency virus-specific effector memory T lymphocyte responses elicited by recombinant adenovirus vectors in rhesus monkeys","volume":"85","author":"Li","year":"2011","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20170511121854_JIS671C40","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.4049\/jimmunol.1101248","article-title":"Vitamin A deficiency impairs vaccine-elicited gastrointestinal immunity","volume":"187","author":"Kaufman","year":"2011","journal-title":"J Immunol"},{"key":"key\n\t\t\t\t20170511121854_JIS671C41","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.4049\/jimmunol.181.6.4188","article-title":"Trafficking of antigen-specific CD8+ T lymphocytes to mucosal surfaces following intramuscular vaccination","volume":"181","author":"Kaufman","year":"2008","journal-title":"J Immunol"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/207\/2\/248\/16866602\/jis671.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T02:20:42Z","timestamp":1562293242000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article-lookup\/doi\/10.1093\/infdis\/jis671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,2]]},"references-count":41,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2012,11,2]]},"published-print":{"date-parts":[[2013,1,15]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jis671","relation":{},"ISSN":["1537-6613","0022-1899"],"issn-type":[{"value":"1537-6613","type":"electronic"},{"value":"0022-1899","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11,2]]}}}